Evguenia S Svarovskaia

Summary

Affiliation: Gilead Sciences
Country: USA

Publications

  1. ncbi request reprint Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine
    Evguenia S Svarovskaia
    Gilead Sciences, Inc, Durham, NC, USA
    J Acquir Immune Defic Syndr 46:174-80. 2007
  2. pmc The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study
    Joy Y Feng
    Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, California 94404, USA
    Retrovirology 6:44. 2009
  3. pmc Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy
    Evguenia S Svarovskaia
    Gilead Sciences, Inc, Foster City, CA, USA
    J Clin Microbiol 50:3267-74. 2012
  4. doi request reprint The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation
    Evguenia S Svarovskaia
    Gilead Sciences, Inc, 4 University Place, 4611 University Drive, Durham, NC 27707, USA
    J Acquir Immune Defic Syndr 48:428-36. 2008
  5. pmc MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples
    Evguenia S Svarovskaia
    Gilead Sciences, Inc, 4 University Place, 4611 University Drive, Durham, NC 27707, USA
    J Clin Microbiol 44:4237-41. 2006
  6. ncbi request reprint Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients
    Joshua M Waters
    Gilead Sciences, Inc, Durham, NC, USA
    Antivir Ther 14:231-9. 2009
  7. doi request reprint Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy
    Derrick D Goodman
    Gilead Sciences Inc, Durham, North Carolina, USA
    AIDS 25:325-33. 2011
  8. pmc Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samples
    Andrew S Bae
    Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA 94404, USA
    J Clin Microbiol 49:3168-74. 2011
  9. pmc Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration
    Jean L Mbisa
    HIV Drug Resistance Program, SAIC Frederick, Inc, National Cancer Institute Frederick, Frederick, MD 21702 1201, USA
    J Virol 81:7099-110. 2007
  10. doi request reprint No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus
    Andrea Snow-Lampart
    Gilead Sciences, Incorporated, Durham, NC, USA
    Hepatology 53:763-73. 2011

Collaborators

Detail Information

Publications16

  1. ncbi request reprint Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine
    Evguenia S Svarovskaia
    Gilead Sciences, Inc, Durham, NC, USA
    J Acquir Immune Defic Syndr 46:174-80. 2007
    ..Prior abacavir (ABC) or didanosine (ddI) therapy can result in the L74V/I or K65R mutation in HIV-1 reverse transcriptase. Preexisting K65R may have an impact on the treatment response to tenofovir disoproxil fumarate (TDF)...
  2. pmc The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study
    Joy Y Feng
    Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, California 94404, USA
    Retrovirology 6:44. 2009
    ....
  3. pmc Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy
    Evguenia S Svarovskaia
    Gilead Sciences, Inc, Foster City, CA, USA
    J Clin Microbiol 50:3267-74. 2012
    ..6 to 3.8 log(10) with NS3 protease inhibitor monotherapy that does not suppress the identified preexisting NS3 DRMs and thus a need for a combination therapy...
  4. doi request reprint The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation
    Evguenia S Svarovskaia
    Gilead Sciences, Inc, 4 University Place, 4611 University Drive, Durham, NC 27707, USA
    J Acquir Immune Defic Syndr 48:428-36. 2008
    ..In clinical isolates, K65R is frequently accompanied by the A62V and S68G reverse transcriptase mutations...
  5. pmc MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples
    Evguenia S Svarovskaia
    Gilead Sciences, Inc, 4 University Place, 4611 University Drive, Durham, NC 27707, USA
    J Clin Microbiol 44:4237-41. 2006
    ..Fifty-three treatment-naïve and 20 treatment-experienced specimens were successfully genotyped with the new method. Results were in agreement with population sequencing and the labor-intensive single-genome sequencing method...
  6. ncbi request reprint Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients
    Joshua M Waters
    Gilead Sciences, Inc, Durham, NC, USA
    Antivir Ther 14:231-9. 2009
    ..Antiretroviral therapy that targets HIV type-1 (HIV-1) reverse transcriptase (RT) can be linked to mutations in the thumb-connection (amino acids [AA] 241-426) and RNase H (AA 427-560) domains, which could affect drug resistance...
  7. doi request reprint Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy
    Derrick D Goodman
    Gilead Sciences Inc, Durham, North Carolina, USA
    AIDS 25:325-33. 2011
    ..Here, we analyzed whether the presence of low levels of K103N at baseline correlated with virologic failure...
  8. pmc Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samples
    Andrew S Bae
    Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA 94404, USA
    J Clin Microbiol 49:3168-74. 2011
    ..5% to 3.0% detected in 5/62 (8%) treatment-naïve patient samples. These findings suggest the need for combination therapy with HCV-specific inhibitors to avoid viral rebound of preexisting mutant HCV...
  9. pmc Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration
    Jean L Mbisa
    HIV Drug Resistance Program, SAIC Frederick, Inc, National Cancer Institute Frederick, Frederick, MD 21702 1201, USA
    J Virol 81:7099-110. 2007
    ..These novel observations suggest that HIV-1 cDNA produced in the presence of A3G exhibits defects in primer tRNA processing, plus-strand DNA transfer, and integration...
  10. doi request reprint No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus
    Andrea Snow-Lampart
    Gilead Sciences, Incorporated, Durham, NC, USA
    Hepatology 53:763-73. 2011
    ..Persistent viremia (≥400 copies/mL) through week 144 was rare (5/641, 0.8%) and was not associated with virological resistance to TDF by population or clonal analyses...
  11. ncbi request reprint Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs
    Evguenia S Svarovskaia
    HIV Drug Resistance Program and AIDS Vaccine Program, Science Applications International Corporation Frederick, Inc, NCI Frederick, National Institutes of Health, Frederick, Maryland 21702, USA
    J Biol Chem 279:35822-8. 2004
    ....
  12. pmc Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness
    Michael E Abram
    Gilead Sciences, Inc, Foster City, California, USA
    Antimicrob Agents Chemother 57:2654-63. 2013
    ..Greater reductions in viral fitness of dual mutation combinations may explain why some primary INSTI RAMs do not readily coexist on the same HIV-1 genome but rather establish independent pathways of resistance to EVG...
  13. pmc Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency
    Galina N Nikolenko
    HIV Drug Resistance Program, NCI Frederick, Bldg 535, Rm 334, Frederick, MD 21702, USA
    J Virol 78:8761-70. 2004
    ..These results also indicate that mutations conferring resistance to antiviral drugs can increase the frequency of RT template switching and may influence the rate of retroviral recombination and viral evolution...
  14. pmc A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion
    Hongzhan Xu
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 101:5652-7. 2004
    ..The HIV-1 Vif-resistant mutant APOBEC3G could provide a gene therapy approach to combat HIV-1 infection...
  15. pmc Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions
    Evguenia S Svarovskaia
    HIV Drug Resistance Program Laboratory of Medicinal Chemistry, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA
    J Virol 78:3210-22. 2004
    ..Thus, sequencing analysis of 2-LTR-circle junctions can elucidate the intracellular mechanisms of action of HIV-1 IN inhibitors...
  16. ncbi request reprint Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors
    Godwin C G Pais
    Laboratory of Medicinal Chemistry, Laboratory of Molecular Pharmacology, and HIV Drug Resistance Program, Center for Cancer Research, National Cancer Institute NIH, 376 Boyles Street, Frederick, MD 21702 1201, USA
    J Med Chem 45:3184-94. 2002
    ..Interestingly, several analogues of L-708,906 with varied substituents on the left side aryl ring, while having good inhibitory potencies against IN in extracellular assays, are not antiviral in whole-cell systems...